Drug device manufacturer Phillips-Medisize has announced plans to open a new 80,000 square foot facility on its Menomonie, Wisconsin site.
The facility, which is projected to be completed in 2017, will manufacture high volume pre-filled drug delivery systems. Over 100 jobs are expected to be created at the facility which is being driven by the signing of a new supply contract with a major biopharmaceutical company.
Matt Jennings, CEO and president of Phillips-Medisize said: “This expansion illustrates our continued commitment and investment in the design and manufacturing of drug delivery devices for biopharmaceutical companies, globally. Expanding in Menomonie adds to our manufacturing capacity to produce fully assembled and packaged drug delivery devices. We are proud of this leading-edge manufacturing campus featuring advanced moulding and assembly, cold-chain drug handling, serialisation technologies and FDA-registered dedicated clinical and pilot build facilities for drug delivery and finished combination products.”
“The recent acquisition of Phillips-Medisize by Molex bolsters our ability to provide comprehensive end- to-end electronics solutions as part of our drug delivery device capabilities. Customer response to our addition of Molex electronics capabilities has been tremendous,” Jennings said.
Phillips-Medisize has been expanding over the last four years in areas such as contract design, development and manufacturing capabilities to service the drug delivery, consumable diagnostics and medical/surgical customers.
The company is also helping provide technical resources and an educated work force through its collaboration with the University of Wisconsin-Stout. This is to help meet the growing demand of the drug delivery industry.